Invasive NSTEMI Strategy Shows No Benefit in Frail Patients - Quiz - MDSpire

Invasive NSTEMI Strategy Shows No Benefit in Frail Patients

Frailty severity may identify older patients least likely to benefit—and potentially at higher risk—with invasive management.

  • By

  • Kathryn Wighton

  • May 6, 2026

  • 4 min

Share

Original Source(s)

Invasive NSTEMI Strategy Shows No Benefit in Frail Patients

  • by Kathryn Wighton

  • May 6, 2026

Related Content

Elevated angiography-derived microvascular resistance and HbA1c levels jointly predict adverse outcomes in patients with diabetic STEMI: a multicenter retrospective cohort study

Case Report: Fabry disease mimicking coronary artery disease and hypertrophic cardiomyopathy—a 15-year diagnostic delay

Comparative efficacy of continuous versus intermittent administration of furosemide in acute heart failure: an updated systematic review and meta-analysis of 22 RCTs